Kazia Therapeutics Ltd

Receive alerts
Market Cap:
$27.04 m
52 weeks high
52 weeks low

Filter by article type

Viewing results 1-25 of 27


Kazia Therapeutics wins ANZLF Trans-Tasman Innovation and Growth award

The awards are run by the Australian New Zealand Leadership Forum which brings senior businesses and government leaders together to help both nations prosper in the global economy. ...

3 days, 19 hours ago

Kazia Therapeutics confirms successful completion of phase I study of its childhood cancer drug

Toxicity can be a significant challenge in the treatment of childhood cancer, so it is very encouraging that GDC-0084 appears to have an acceptable tolerability profile....

4 days, 15 hours ago

Kazia Therapeutics' cancer drug trials lift valuation to $137 million or $2.20 a share, according to Edison

The report points out Kazia’s accelerated 2023 GDC-0084 approval and maintains its base case 2024 launch scenario with an updated valuation. ...

1 week, 1 day ago

Kazia Therapeutics a top-10 finalist in ANZLF Trans-Tasman Innovation and Growth Awards

The four award winners will be announced at a dinner in Auckland, New Zealand, next Thursday, September 12, presented by NZ Prime Minister Jacinta Arden....

1 week, 4 days ago

Kazia Therapeutics continues to progress clinical assets into FY2020

If GDC-0084 is successful in phase-III, the drug will launch into a disease area that has been poorly served by the last two decades of progress in cancer treatment. ...

2 weeks, 5 days ago

Kazia Therapeutics designated name for brain cancer drug by World Health Organisation

Selection of an INN is usually a necessary step before a new drug can be submitted for commercial registration. ...

3 weeks, 4 days ago

Kazia Therapeutics concludes recruitment into Part B of its phase I ovarian cancer clinical study

About 240,000 women are diagnosed with ovarian cancer each year worldwide and it is the eighth most common cause of cancer death in women. ...

on 13/8/19

Kazia Therapeutics to begin phase I clinical trial for cancer that has spread to the brain

Memorial Sloan Kettering Cancer Center in New York will investigate the potential use of Kazia’s investigational new drug, GDC-0084....

on 22/7/19

Kazia Therapeutics substantial holder Willoughby Capital increases interest to 17.52%

Edison Investment Research has assigned an indicative valuation range of $84–135 million or $1.35–2.17 per share for Kazia....

on 10/7/19

Kazia Therapeutics substantial shareholder lifts interest to 17.4%

Sydney-based Hishenk Pty Ltd now holds 10.835 million shares after placement and on-market purchases....

on 4/7/19

Kazia Therapeutics has two novel classes of anti-cancer drugs: Edison Investment Research

A new collaboration with the Alliance for clinical trials in oncology means Kazia will soon have four clinical trials of GDC-0084 underway in primary or secondary brain cancers. ...

on 28/6/19

Gold Coast Investment Showcase will feature companies from diverse range of sectors

The conference will be held next Tuesday and Wednesday at Surfers Paradise Marriott Resort & Spa....

on 21/6/19

Kazia Therapeutics to collaborate with US-based oncology foundation on clinical trials for metastatic brain cancer treatment

The study will mark the fourth ongoing clinical trial for Kazia's GDC-0084 drug candidate, with each trial treating different forms of brain cancer. ...

on 20/5/19

Kazia Therapeutics gains new substantial holder in The Bank of New York Mellon

The company plans to begin recruitment for its upcoming dose expansion cohort immediately. ...

on 8/5/19

Kazia Therapeutics' ongoing study confirms higher drug tolerability in newly-diagnosed glioblastoma patients

The company will begin recruitment for the upcoming dose expansion cohort immediately. ...

on 6/5/19

Kazia Therapeutics studies evaluate therapeutic candidates in ovarian cancer and brain tumours

The oncology-focused biotech is a mid-clinical-stage therapeutics company....

on 2/5/19

Proactive CEO Sessions in Sydney and Melbourne next week feature five companies

The Sydney session is on Monday, February 18 and the Melbourne session is on the following day, February 19....

on 15/2/19

Theta Gold Mines to outline South African gold strategy at Proactive CEO Session

The company has near-term catalysts including an upgraded resource statement and a feasibility study....

on 12/2/19

Kazia Therapeutics will outline anti-cancer drug development strategy at CEO Sessions

The company’s CEO James Garner will present to investors in Sydney and Melbourne....

on 7/2/19

Anatara Lifesciences to outline its new strategy in human health at Proactive CEO Sessions

Following the successful licencing of its animal health product to Zoetis Inc, Anatara is now focused on building a pipeline of human gastrointestinal health products....

on 6/2/19

Argonaut Resources to talk Lake Torrens at Proactive CEO Sessions

The company’s CEO Lindsay Owler will address investors at the CEO Sessions....

on 6/2/19

Peninsula Energy will update on uranium transition progress at Proactive CEO Sessions

The transition to low pH operations at the Lance Projects is expected to enhance recovery and lower operating costs....

on 5/2/19

AdAlta will outline fibrosis treatment progress during Proactive CEO Sessions

The i-body technology platform of AdAlta is initially focused on treating fibrotic diseases, such as IPF....

on 4/2/19